脾氨肽口服液治疗变应性鼻炎的疗效及对T淋巴细胞亚群免疫平衡的影响

  目的  探究脾氨肽口服液用于变应性鼻炎治疗的临床效果，并分析其对患者血清T淋巴细胞亚群的影响。  方法  选取2018年4月—2019年5月宁波大学医学院附属医院收治的变应性鼻炎患者93例，采用随机数字表法分为脾氨肽组(46例)与常规组(47例)，对比2组临床疗效、T淋巴细胞亚群、免疫功能及生活质量。  结果  脾氨肽组总有效率高于常规组(P=0.031)；治疗后，脾氨肽组CD3+[(70.33±6.89)%]、CD4+[(39.28±4.31)%]及CD4+/CD8+(1.64±0.39)均高于常规组[(59.46±7.26)%、(36.04±4.76)%、1.35±0.43，均P＜0.001]，CD8+[(24.12±2.38)%]低于常规组[(26.34±2.11)%，P＜0.001]；治疗后脾氨肽组血清白介素-2[(75.52±10.48)pg/mL]、γ-干扰素[(85.56±6.24)pg/mL]高于常规组[(69.27±8.53)pg/mL、(68.81±7.07)pg/mL]，白介素-4[(115.58±34.45)pg/mL]、白介素-5[(625.64±114.28)pg/mL]水平低于常规组[(168.37±40.22)pg/mL、(837.57±117.49)pg/mL，均P＜0.001]；治疗后脾氨肽组鼻结膜炎生活质量评分低于常规组(P＜0.001)。  结论  脾氨肽口服液可提高变应性鼻炎疗效，发挥免疫调节作用，减轻机体变态反应与临床症状。 

The therapeutic effect of Spleen Aminopeptide Oral Solution on allergic rhinitis and immune balance of T lymphocyte subsets

  Objective  To explore the therapeutic effect of Spleen Aminopeptide Oral Solution on allergic rhinitis and immune balance of T lymphocyte subsets.  Methods  A total of 93 patients with allergic rhinitis admitted to our hospital were randomly divided into Spleen Aminopeptide group (n=46) and regular group (n=47) according to the random number table method. The clinical efficacy, T lymphocyte subsets, immune function and quality of life of the two groups were compared.  Results  The total effective rate of the Spleen Aminopeptide group which was higher than that of the regular group (P=0.031). After treatment, the CD3+ [(70.33±6.89)%]、CD4+ [(39.28±4.31)%] and CD4+/CD8+ (1.64±0.39) in the Spleen Aminopeptide group were higher than those in the regular group [(59.46±7.26)%、(36.04±4.76)%、1.35±0.43, all P < 0.001], and the CD8+[(24.12±2.38)%] was lower than that in the regular group [(26.34±2.11)%, P < 0.001]. After treatment, the levels of serum interleukin-2 [(75.52±10.48) pg/mL] and interferon-γ [(85.56±6.24) pg/mL] in the Spleen Aminopeptide group were higher than those in the regular group [(69.27±8.53) pg/mL, (68.81±7.07) pg/mL], the levels of serum interleukin-4 [(115.58±34.45) pg/mL] and serum interleukin-5 [(625.64±114.28) pg/mL] were lower than those in the regular group [(168.37±40.22) pg/mL, (837.57±117.49) pg/mL, all P < 0.001]. After treatment, the rhinoconjunctivitis quality of life questionnaire (RQLQ) score of the Spleen Aminopeptide group was lower than that of the regular group (P < 0.001).  Conclusion  Spleen Aminopeptide Oral Solution can improve the curative effect of allergic rhinitis, play the role of immune regulation, reduce the body allergy and clinical symptoms.